Inside the Cost Projections That Help Centene Win Big Medicaid Contracts

State Medicaid contracts worth billions are awarded based on cost projections. The company promising the lowest cost per member typically wins — assuming they meet minimum quality standards.

This creates powerful incentives to lowball initial bids, then find ways to increase revenue or reduce costs after winning.

Centene has mastered this game.

The Bidding Process

When states issue Medicaid managed care RFPs, companies submit detailed financial projections: expected costs per member, administrative expenses, profit margins, premium rates.

States evaluate bids on multiple factors, but cost is typically weighted heavily. A company promising to manage care for $400 per member per month has an advantage over competitors projecting $450.

The question is: How accurate are those projections?

The Post-Award Reality

Centene consistently wins contracts with aggressive pricing. Then, systematically, the costs don’t match projections.

Administrative costs initially projected at 8–10% somehow climb to 12–15% once operations begin. The company cites “unforeseen complexity” or “unique state requirements” as justification.

Pharmacy costs turn out higher than modeled. Centene’s PBM charges the plan more than projected, increasing overall costs while generating profit for the related entity.

Medical costs are managed not through better care coordination (as promised) but through aggressive utilization management — denying or delaying care to hit financial targets.

Network adequacy is achieved on paper through contracts that providers later claim they never agreed to or that contain reimbursement rates making participation unviable.

The Contract Modification Strategy

Here’s where it gets sophisticated: initial contract rates are locked for one or two years. After that, Centene requests rate increases citing higher-than-expected costs.

States face a dilemma: Deny the increase and risk the company exiting the market (disrupting care for hundreds of thousands), or approve increases that make the “low-cost” bid meaningless.

Most states approve increases. The alternative — finding a new contractor mid-stream — is operationally and politically untenable.

Centene knows this. The initial low bid gets them in the door. Subsequent rate increases generate the actual margins they always intended to achieve.

The Quality Score Manipulation

Medicaid contracts typically include quality metrics. Higher quality scores can justify higher reimbursement rates or contract renewals.

Centene has developed sophisticated methods for gaming quality measures:

Cherry-picking easier-to-manage populations for specific programs. Aggressive outreach only for members likely to improve measured outcomes. Data reporting that emphasizes favorable metrics while downplaying poor performance. “Focused improvement” on whatever measures the state weights most heavily in contract evaluations.

This creates the appearance of quality improvement without necessarily delivering better care systemwide.

The Evidence

Multiple state audits have revealed consistent patterns: Centene’s actual costs and performance differing significantly from initial projections, administrative expenses higher than bid, profit margins exceeding contracted amounts, and quality improvements concentrated in measured areas while unmeasured aspects of care stagnate.

Yet the company continues winning new contracts with similar aggressive pricing strategies.

Why This Persists

State procurement officials face pressure to select the lowest-cost bid. Choosing a higher bidder requires extensive justification.

By the time actual costs emerge post-award, the officials who approved the contract may have moved on. Accountability is diffuse.

And states lack leverage once contracts are signed. Switching contractors is extraordinarily disruptive.

The Fix

States should weight bidder track record more heavily. Companies with patterns of cost overruns should face skepticism on new low-ball bids.

Contracts should include stronger performance penalties for missing cost projections — not just allowing rate increases when companies claim costs are higher than expected.

Independent auditing of cost allocation should be built into contracts from day one, not conducted years later after problems emerge.

Until procurement processes change, expect more of the same: aggressive bids that win contracts, followed by cost increases that make those bids meaningless.

Taxpayers fund the difference. Patients receive the care that Centene’s actual cost structure — not their bid projections — can support.